The use of NGAL and IP-10 in the prediction of early acute rejection in highly sensitized patients following HLA-incompatible renal transplantation

Transplant International

Volumn 27, Issue 4, 2014, Pages 362-370

  Field, Melanie ^a   Lowe, David ^b   Cobbold, Mark ^c   Higgins, Robert ^d   Briggs, David ^b   Inston, Nicholas ^a   Ready, Andrew R ^a  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^b Histocompatibility and Immunogenetics Laboratory   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d UNIVERSITY HOSPITALS COVENTRY AND WARWICKSHIRE NHS TRUST   (United Kingdom)

Author keywords

HLA; IP 10; kidney transplant; NGAL; rejection

Indexed keywords

BASILIXIMAB; CATHEPSIN L; CYSTATIN C; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; KIDNEY INJURY MOLECULE 1; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PREDNISOLONE; TACROLIMUS; VASCULOTROPIN; ACUTE PHASE PROTEIN; BIOLOGICAL MARKER; CXCL10 PROTEIN, HUMAN; LCN2 PROTEIN, HUMAN; LIPOCALIN; ONCOPROTEIN;

ACUTE GRAFT REJECTION; ADULT; AGED; ANTIBODY MEDIATED REJECTION; ARTICLE; CELL MEDIATED CYTOTOXICITY; CONTROLLED STUDY; DELAYED GRAFT FUNCTION; DESENSITIZATION; FEMALE; FLOW CYTOMETRY; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT SURVIVAL; HIGH RISK PATIENT; HISTOCOMPATIBILITY; HISTOINCOMPATIBILITY; HLA MATCHING; HLA SYSTEM; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOSURVEILLANCE; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; ACUTE DISEASE; ADOLESCENT; BLOOD; COHORT ANALYSIS; GRAFT REJECTION; HISTOCOMPATIBILITY TEST; MIDDLE AGED; RETROSPECTIVE STUDY; RISK FACTOR; TIME; YOUNG ADULT;

ACUTE DISEASE; ACUTE-PHASE PROTEINS; ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; CHEMOKINE CXCL10; COHORT STUDIES; FEMALE; GRAFT REJECTION; HISTOCOMPATIBILITY TESTING; HUMANS; KIDNEY TRANSPLANTATION; LIPOCALINS; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; YOUNG ADULT;

EID: 84899456778     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/tri.12266     Document Type: Article

References (30)

1. Puttarajappa C, Shapiro R, Tan H,. Antibody-mediated rejection in kidney transplantation: a review. J Transplant 2012; 2012: 9.
2. Nankivell BJ, Alexander S,. Rejection of the kidney allograft. N Engl J Med 2010; 363: 1451.
3. Gloor J, Winters J, Cornell L, et al,. Baseline donor-specific antibody levels and outcomes in positive crossmatch kidney transplantation. Am J Transplant 2010; 10: 582.
4. Thielke J, West-Thielke P, Herren H, et al,. Living donor kidney transplantation across positive crossmatch: the University of Illinois at Chicago experience. Transplantation 2009; 87: 268.
5. Vo A, Peng A, Toyoda M, et al,. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation. Transplantation 2010; 89: 1095.
6. Haririan A, Nogueira J, Kukuruga D, et al,. Positive cross-match living donor kidney transplantation: longer-term outcomes. Am J Transplant 2009; 9: 536.
7. Higgins R, Lowe D, Hathaway M, et al,. Human leukocyte antigen antibody-incompatible renal transplantation: excellent medium-term outcomes with negative cytotoxic crossmatch. Transplantation 2011; 92: 900.
8. Heidt S, San Segundo D, Sushma S, et al,. Peripheral blood sampling for the detection of allograft rejection: biomarker identification and validation. Transplantation 2011; 92: 1.
9. Hamer R, Roche L, Smillie D, et al,. Soluble CD30 and Cd27 levels in patients undergoing HLA antibody incompatible renal transplantation. Transpl Immunol 2010; 23: 161.
10. luminex. Sample protocol for washed capture sandwich immunoassay. 2006; Available from: http://www.luminexcorp.com/prod/groups/public/documents/ lmnxcorp/washed-capture-sandwich.pdf.
11. Solez K, Colvin RB, Racusen LC, et al,. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant 2008 Apr; 8: 753.
12. Higgins R, Zehnder D, Chen K, et al,. The histological development of acute antibody-mediated rejection in HLA antibody-incompatible renal transplantation. Nephrol Dial Transplant 2010; 25: 1306.
13. Solez K, Racusen LC,. The Banff classification revisited. Kidney Int 2013; 83: 201.
14. Taube D, Williams D, Cameron J, et al,. Renal transplantation after removal and prevention of resynthesis of HLA antibodies. Lancet 1984; 1: 824.
15. Group BDW. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69: 89.
16. Romagnani P, Crescioli C,. CXCL10: a candidate biomarker in transplantation. Clin Chim Acta 2012; 413: 1364.
17. Hancock W, Lu B, Gao W, et al,. Requirement of the chemokine receptor CXCR3 for acute allograft rejection. J Exp Med 2000; 192: 1515.
18. Matz M, Beyer J, Wunsch D, et al,. Early post-transplant urinary IP-10 expression after kidney transplantation is predictive of short- and long-term graft function. Kidney Int 2006; 69: 1683.
19. Hancock W, Gao W, Csizmadia V, Faia K, Shemmeri N, Luster A,. Donor-derived IP-10 initiates development of acute allograft rejection. J Exp Med 2001; 193: 975.
20. Tatpudi R, Muthukumar T, Dadhania D, et al,. Noninvasive detection of renal allograft inflammation by measurements of mRNA and IP-10 and CXCR3 in urine. Kidney Int 2004; 65: 2390.
21. Bonecchi R, Bianchi G, Bordignon PP, et al,. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J Exp Med 1998; 187: 129.
22. Hu H, Aizenstein BD, Puchalski A, Burmania JA, Hamawy MM, Knechtle SJ,. Elevation of CXCR3-binding chemokines in urine indicates acute renal-allograft dysfunction. Am J Transplant 2004; 4: 432.
23. Lazzeri E, Rotondi M, Mazzinghi B, et al,. High CXCL10 expression in rejected kidneys and predictive role of pretransplant serum CXCL10 for acute rejection and chronic allograft rejection. Transplantation 2005; 79: 1215.
24. Haase M, Bellomo R, Haase-Fielitz A,. Neutrophil gelatinase-associated lipocalin. Curr Opin Crit Care 2010; 16: 526.
25. Bennett M, Dent CL, Ma Q, et al,. Urine NGAL predicts severity of acute kidney injury after cardiac surgery: a prospective study. Clin J Am Soc Nephrol 2008; 3: 665.
26. Wagener G, Jan M, Kim M, et al,. Association between increases in urinary neutrophil gelatinase-associated lipocalin and acute renal dysfunction after adult cardiac surgery. Anaesthesiology 2006; 105: 485.
27. Haase M, Bellomo R, Devarajan P, Schlattmann P, Haase-Fielitz A,. Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis 2009; 54: 1012.
28. Hollmen ME, Kyllönen LE, Inkinen KA, Lalla MLT, Salmela KT,. Urine neutrophil gelatinase-associated lipocalin is a marker of graft recovery after kidney transplantation. Kidney Int 2010; 79: 89.
29. Heyne N, Kemmner S, Schneider C, Nadalin S, Konigsrainer A, Haring H,. Urinary Neutrophil Gelatinase-Associated Lipocalin accurately detects acute allograft rejection among other causes of acute kidney injury in renal allograft recipients. Transplantation 2012; 93: 1252.
30. Higgins R, Lowe D, Hathaway M, et al,. Rises and falls in donor-specific and third-party HLA antibody levels after antibody incompatible transplantation. Transplantation 2009; 87: 882.